BHCM
LCTX icon

Brevan Howard Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Brevan Howard Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$295K Buy
+186,794
New +$315K ﹤0.01% 1634
2025
Q3 		– Sell
-308,877
Closed -$281K – 2143
2025
Q2 		$281K Buy
+308,877
New +$183K ﹤0.01% 1575

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brevan Howard Capital Management's LCTX Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q1 2026: 186,794 shares worth $295K. The stake represents ﹤0.01% of the portfolio and ranks #1634 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in LCTX as recently as Q2 2025.

Brevan Howard Capital Management first reported a position in LCTX in Q2 2025 and has held it in 2 quarters since. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Brevan Howard Capital Management held 186,794 shares of Lineage Cell Therapeutics worth $295K as of Q1 2026.
  • Lineage Cell Therapeutics was a new Brevan Howard Capital Management position in Q1 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1634 holding.
  • Brevan Howard Capital Management first reported a position in Lineage Cell Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.